VANCOUVER, British Columbia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F)
(the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of
pharmaceutical and nutraceutical products, announced today that Isodiol’s common shares have been approved for trading on the OTCQB
Venture Market in the United States. The trading symbol will remain as ISOLF.
The OTCQB is the ideal exchange for emerging companies. To be eligible for the OTCQB, companies must be up to date in
reporting with the U.S. Securities Exchange Commission, meet a minimum price bid test, and undergo an annual verification and
management certification process. These standards and regulations will provide investors with confidence and enhance their
trading experiences.
“We are very pleased with this OTCQB listing. Listing on the OTCQB is part of Isodiol’s overall strategy to increase
awareness to international investors,” said Marcos Agramont, CEO of Isodiol. “This listing will provide the Company with a
significant trading platform for international shareholders and future investors, while making the Company itself easily available
to American investors.”
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and
nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer
products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive
pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin
care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical
portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
Forward-Looking Information: This news release contains "forward-looking
information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and
future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the
expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will
prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking
statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially
from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will
vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as
required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or
forward-looking information in this news release. Although the Company believes that the expectations reflected in the
forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no
reference to profitability based on sales reported. The statements in this news release are made as of the date of this
release.
The CSE has not reviewed, approved or disapproved the content of this press release.
